CEBPZ and acute myeloid leukemia: In summary, BIRC5 expression appears to be able to predict better outcomes at least in a subset of CBF-AML cases (those with inv(16)) suggesting that this LAA may provide an immunologically relevant personalised target for a sub-group of AML patients.